Genomic Health, Inc. (GHDX): Price and Financial Metrics
GHDX Stock Summary
- GHDX's current price/earnings ratio is 44.63, which is higher than 83.63% of US stocks with positive earnings.
- The price/operating cash flow metric for NA is higher than 85.42% of stocks in our set with a positive cash flow.
- Over the past twelve months, GHDX has reported earnings growth of 194.66%, putting it ahead of 93.48% of US stocks in our set.
- Stocks that are quantitatively similar to GHDX, based on their financial statements, market capitalization, and price volatility, are OMCL, OSIS, PCTY, QDEL, and SPSC.
GHDX Stock Price Chart More Charts
GHDX Price/Volume Stats
|Current price||$63.44||52-week high||$90.18|
|Prev. close||$63.88||52-week low||$50.77|
|Day high||$64.57||Avg. volume||586,356|
|50-day MA||$69.75||Dividend yield||N/A|
|200-day MA||$67.25||Market Cap||2.38B|
Genomic Health, Inc. (GHDX) Company Bio
Genomic Health provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company was founded in 2000 and is based in Redwood City, California.